Human papillomavirus vaccine for cancer cervix prevention: Rationale & recommendations for implementation in India

• Published in: Indian journal of medical research (New Delhi, India : 1994) Vol. 146; no. 2; pp. 153 - 157
• Main Authors: Kaur, Prabhdeep, Mehrotra, Ravi, Rengaswamy, Sankaranarayanan, Kaur, Tanvir, Hariprasad, Roopa, Mehendale, Sanjay M, Rajaraman, Preetha, Rath, G K, Bhatla, Neerja, Krishnan, Suneeta, Nayyar, Anjali, Swaminathan, Soumya
• Format: Journal Article
• Language: English
• Published: India Medknow Publications and Media Pvt. Ltd 01.08.2017; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd
• Subjects: Cervical cancer; Cervix Uteri - immunology; Cervix Uteri - pathology; Dosage and administration; Female; Human papillomavirus; Humans; India - epidemiology; Papillomavirus Infections - epidemiology; Papillomavirus Infections - immunology; Papillomavirus Infections - prevention & control; Papillomavirus Infections - virology; Papillomavirus vaccines; Papillomavirus Vaccines - adverse effects; Papillomavirus Vaccines - therapeutic use; Practice guidelines (Medicine); Prevention; Studies; Uterine Cervical Neoplasms - epidemiology; Uterine Cervical Neoplasms - immunology; Uterine Cervical Neoplasms - prevention & control; Uterine Cervical Neoplasms - virology; Vaccination; Vaccines; Viewpoint; Womens health; India
• ISSN: 0971-5916
• DOI: 10.4103/ijmr.IJMR_1906_16

India contributed to one-fourth of the global burden of cervical cancer in 2000. [...]researchers emphasized the need for population-based interventions in India to reduce the overall burden of cervical cancer globally[3]. A multidisciplinary Expert Group constituted by the Secretary, Department of Health Research (DHR) and Director-General (DG), Indian Council of Medical Research, Ministry of Health and Family Welfare, Government of India, reviewed the available evidence globally regarding immunogenicity and efficacy, adverse effects and cost-effectiveness of the HPV vaccine. HPV infections, precancerous lesions and anogenital warts A systematic review of 20 studies from nine high-income countries analyzed the risk reduction in the HPV infection and anogenital warts in the vaccinated cohorts[9]. Protection is for only selected HPV types and does not cover all high-risk types. [...]comprehensive cervical cancer control also requires cervical cancer screening for early detection and treatment, even for those cohorts vaccinated against HPV.